Lenz Therapeutics rises after securing FDA nod for its eye-disorder treatment

LENZ Therapeutics

31/07/2025 22:51

** Shares of drugmaker Lenz Therapeutics LENZ.O rise 3.6% to $30.83 in extended trading

** Co says the FDA approved its treatment, with the brand name VIZZ for a type of eye disorder known as Presbyopia

** Presbyopia or age-related blurry near vision, is the loss of clear close-up vision that happens when the eye’s lens becomes less flexible

** VIZZ is once-a-day eye drop developed to restore clear near vision for up to 10 hours

** The treatment is the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, the company says

** The commercial product is expected to be available by mid-Q4 2025, the company says

** Stock up 3.1% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))